Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers
Who can join
Ages 40 to 75 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Ages between 40 to 75 years old. * History of at least 20 pack-years of smoking. * No diagnosis of COPD or asthma. * No spirometric evidence of airflow obstruction as determined by FEV1/FVC ratio ≥0.7. * FEV1 and FVC \>lower limit of normal. * Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months. * Subjects will be divided into two groups by their RV/TLC: Normal RV/TLC Group: • Plethysmographic RV/TLC equal or less than lower limit of normal. Abnormal RV/TLC Group: • Plethysmographic RV/TLC higher than lower limit of normal. Exclusion Criteria: * Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage. * Marijuana use \>400 joints in lifetime or any within past 6 months. * Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level. * Pregnant/breast feeding. * Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy. * Liver cirrhosis. * History of chronic active Hepatitis B or C.
About the study
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.
What is being tested
- Bronchoscopy with Bronchoalveolar Lavage (BAL) (procedure)
Sponsor: University of California, San Francisco · Participants: 40 · Started: Mar 1, 2021
Contact the study team
- Yorusaliem Abrham · Phone: 415-221-4810
- Helen Lozier, B.A. · Phone: (415) 609-6738
Official record on ClinicalTrials.gov — NCT04722835
Locations in the U.S.
| California | San Francisco VA Medical Center, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.